Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 765.50B +5.2% |
| Revenue (ttm) | 55.51B +44.7% |
| Net Income | 17.58B +94.9% |
| EPS | 19.55 +96.0% |
| Shares Out | n/a |
| PE Ratio | 43.55 |
| Forward PE | 29.11 |
| Dividend | 5.37 (0.63%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 125 |
| Average Volume | 276 |
| Open | 872.50 |
| Previous Close | 862.60 |
| Day's Range | 853.10 - 872.90 |
| 52-Week Range | 537.40 - 968.10 |
| Beta | n/a |
| RSI | 45.08 |
| Earnings Date | Feb 4, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Eli Lilly Stock Falls Despite Barclays Giving 'Overweight' Rating on Obesity Drugs
Eli Lilly Stock Falls Despite Barclays Giving 'Overweight' Rating on Obesity Drugs
Barclays Initiates Coverage on Eli Lilly (LLY) with Overweight Rating | LLY Stock News
Barclays Initiates Coverage on Eli Lilly (LLY) with Overweight Rating | LLY Stock News
Salomon & Ludwin, LLC Buys 483 Shares of Eli Lilly and Co (LLY)
Salomon & Ludwin, LLC Buys 483 Shares of Eli Lilly and Co (LLY)
Vanguard Russell 3000 Index Fund Buys 1,235 Shares of Eli Lilly and Co (LLY)
Vanguard Russell 3000 Index Fund Buys 1,235 Shares of Eli Lilly and Co (LLY)
VANGUARD WELLINGTON FUND Sells 228,133 Shares of Eli Lilly and Co (LLY)
VANGUARD WELLINGTON FUND Sells 228,133 Shares of Eli Lilly and Co (LLY)
Eli Lilly Breaks New Ground In Crohn's Disease Treatment
Eli Lilly and Co. (NYSE: LLY) on Thursday released promising long-term data regarding its treatment for Crohn’s disease. This news comes as the company reported that more than 90% of patients maintai...
Warning: This Skyrocketing Stock Has a Hidden Risk
Eli Lilly makes the best-performing GLP-1 drugs on the market today. The company faces intense competition and has a relatively short window of opportunity.
Prediction: Eli Lilly Stock Could Surge 45% This Year
Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price?
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Eli Lilly (LLY) Reports Positive Results for Omvoh in Phase 3 Study
Eli Lilly (LLY) Reports Positive Results for Omvoh in Phase 3 Study
Eli Lilly unveils long-term data on Omvoh for Crohn's disease
Eli Lilly (LLY) Showcases Long-Term Efficacy of Omvoh for Crohn's Disease
Eli Lilly (LLY) Showcases Long-Term Efficacy of Omvoh for Crohn's Disease
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally l...
3 Stocks to Buy and Hold for 2026 and Beyond
AbbVie is a Dividend King, poised for strong growth with Rinvoq and Skyrizi. Eli Lilly has taken control of the obesity drug market, with major possibilities ahead.
Vanguard Russell 1000 Index Fund Buys 2,841 Shares of Eli Lilly and Co (LLY)
Vanguard Russell 1000 Index Fund Buys 2,841 Shares of Eli Lilly and Co (LLY)
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush
Ozempic is a well-recognized name in the weight loss drug space. The product was the first GLP-1 drug to enter the market after gaining approval in 2017.
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years
Eli Lilly (NYSE: LLY) has outperformed the market over the past 15 years by 13.75% on an annualized basis producing an average annual return of 25.43%. Currently, Eli Lilly has a market capitalizatio...
DFAC, LLY, V, MA: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Dimensional US Core Equity 2 ETF (Symbol: DFAC) where we have detected...
Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects
Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo
Eli Lilly and Co. (NYSE: LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepati...
Eli Lilly (LLY) Achieves Success in Phase 3b Trial for Psoriasis and Weight Loss Therapy
Eli Lilly (LLY) Achieves Success in Phase 3b Trial for Psoriasis and Weight Loss Therapy
Eli Lilly's Taltz-Zepbound Deliver Positive Results At 36 Weeks In Psoriasis And Obesity Trial
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) announced positive topline results from the TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz and Zepboun...
Eli Lilly (LLY) Clinical Trial Shows Improved Psoriasis Outcomes with Combination Therapy
Eli Lilly (LLY) Clinical Trial Shows Improved Psoriasis Outcomes with Combination Therapy
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study
Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better results in a late-stage study.
Eli Lilly and Company: Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance (PASI 100) and =10% weight loss...